China welcomes foreign friends to add China to their travel bucket list, and experience China's time-honored history by visiting heritage sites such as the Great Wall, feast their eyes on natural wonders such as the glinting West Lake, discover application of cutting-edge technologies, and feel the spirit of humanity embodied in winter dining delights, Lin Jian, spokesperson from China's Foreign Ministry told a press conference on Tuesday, following the latest visa-free policy update released by China's National Immigration Administration (NIA) on Tuesday morning.

Starting from November 30, 2024, ordinary passport holders from 38 countries can be exempted from visa to enter China and stay for no more than 30 days for business, tourism, family visit, exchange and transit purposes. 

Chinese authorities recently released revised rules on foreign investors' strategic investment in listed companies in a move to encourage foreign investors to make long-term and value investments in the country.

As of 31 October, 2024, all mainland-listed Chinese IVD companies have released their third-quarter financial reports. This summary provides insights into 50 main IVD enterprises and 20 IVD-related enterprises for reference. Notably, Hong Kong-listed companies are not included.

Devyser has achieved a significant regulatory milestone with its first market registration from China’s National Medical Products Administration (NMPA) for Devyser Compact, an IVDR-certified genetic test for detecting fetal chromosomal abnormalities. Rapid prenatal aneuploidy detection kits fall under Class III IVD as part of the NMPA product registration process. This approval enables Devyser to market Devyser Compact as an in vitro diagnostic in China and paves the way for future regulatory approvals in the region for its simple, fast, and accurate genetic testing solutions.

China has seen a surge of entry from foreigners during the third quarter this year, statistics from the National Immigration Administration showed.

From 20 September to 3 October, 2024, CACLP held a series of five successful online promotional webinars, aimed at fostering international collaboration within the in vitro diagnostics (IVD) industry.

Mr. Eui-Yul Choi, Chairman of Korea In Vitro Diagnostic Medical Device Association, CEO of Boditech Med, led a delegation to visit China Association of In-Vitro Diagnostics (CAIVD), on 26 June 2024.

As of 30 April 2024, there were 82 Chinese IVD listed companies, of which 61 were listed companies with main IVD business (IVD business accounted for more than 50% of the total business), and 21 were listed companies with IVD-related business.

The fully automatic biochemistry analyzer, characterized by high technical content, high accuracy, high precision, high flexibility, and high working efficiency, has become one of the indispensable instruments in the modern clinical laboratory for the increasing testing work.